
Loading, please wait...

Loading, please wait...

Managing advanced skin cancer remains a significant clinical challenge for oncologists. A recent real-world study published in The Oncologist evaluated the effectiveness of melanoma brain metastases treatment using stereotactic radiosurgery (SRS) combined with concurrent ipilimumab and nivolumab (ipi/nivo). This research specifically investigated how previous systemic therapy exposure influences survival and intracranial disease control.
Researchers found that patients who were naive to immune checkpoint inhibitors (ICI) showed significantly better survival. For example, ICI-naive patients achieved a median overall survival of 50.5 months. In contrast, those with prior ICI exposure only reached 17.6 months. Consequently, prior therapy status is a crucial predictor of success in the clinical setting. Moreover, intracranial progression-free survival (iPFS) was notably longer in the treatment-naive group, reaching 15.1 months compared to just 5.9 months for those previously treated. Furthermore, this trend suggests that early integration of combined modalities may yield the best results.
Combining SRS with ipi/nivo provides durable intracranial control with a manageable safety profile. Specifically, at the 24-month mark, the local progression rate remained low at 11%. Additionally, the incidence of radionecrosis was only 7%, and leptomeningeal disease occurred in just 4% of cases. However, patients with a high disease burden, defined as 11 or more SRS-treated lesions, faced a significantly higher risk of treatment failure. Therefore, clinicians should carefully assess the number of metastases when planning therapeutic interventions.
The study utilized multivariable analysis to identify several critical prognostic factors. Aside from prior ICI use, previous treatment with BRAF/MEK inhibitors also predicted worse overall survival. On the other hand, a higher Graded Prognostic Assessment (GPA) score favored better outcomes. Because these high-risk subgroups represent a significant portion of the patient population, researchers emphasize the need for intensified or novel treatment strategies. Ultimately, these findings support a personalized approach to managing metastatic melanoma.
Yes, the study demonstrated that patients with prior immune checkpoint inhibitor exposure had a median survival of 17.6 months, compared to 50.5 months in treatment-naive patients.
The combination of SRS and ipi/nivo was relatively well-tolerated, with radionecrosis occurring in only 7% of patients and leptomeningeal disease in 4%.
Patients who have 11 or more brain lesions, a low GPA score, or previous exposure to targeted therapies like BRAF/MEK inhibitors are considered at higher risk for poorer outcomes.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or substitute for professional consultation. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Real-world study reveals that prior ICI or targeted therapy significantly impacts survival in melanoma patients receiving SRS with ipilimumab and nivolumab....
8 months ago

A breakthrough LC-MS/MS technique provides rapid, green quantification of polar pesticide residues like glyphosate across 13 foods. Dietary risk assessment shows negligible toxicity, while discarding initial tea infusions removes up to 99.2% of chemical traces.
Today

Delhi is undergoing a major healthcare overhaul with enhanced Ayushman Bharat insurance up to ₹10 lakh, increased MBBS and PG medical training seats, expanded primary network mandirs, new tertiary neuro-ICUs, and public-private reproductive technology initiatives to build a resilient, preventative healthcare model.
Today

Aon forecasts India's healthcare inflation will ease to 10.1% in 2027 from 11.5% in 2026. Despite moderation, healthcare expenses continue to outpace general inflation, propelled by non-communicable diseases, advanced medical therapeutics, and expanding utilization patterns across diverse patient populations.
Today

Non-union fractures occur in 2-5% of cases, causing significant disability and cost. Conservative modalities such as LIPUS, PEMF, and focused ESWT offer non-surgical healing options for defects up to 5-10 mm when adequate mechanical stability exists without infection.
Yesterday

A crossover trial reveals that acute resistance exercise at 80% 1RM markedly reduces circulating asprosin, enhances insulin sensitivity, and blunts appetite in women with and without obesity, establishing high-intensity lifting as an effective non-pharmacological metabolic therapy.
Today